Literature DB >> 9552343

The evaluation of lyophilized polymer matrices for administering recombinant human bone morphogenetic protein-2.

S S Duggirala1, J B Rodgers, P P DeLuca.   

Abstract

Novel unitary devices, prepared by lyophilization of viscous solutions of sodium carboxymethylcellulose (CMC) and methylcellulose (MC), were evaluated as sustained-release delivery systems for recombinant human bone morphogenetic protein-2 (rhBMP-2). In vitro characterization of the unitary devices, which contained rhBMP-2-loaded poly (d,l lactide-co-glycolide) (PLGA) bioerodible particles (BEPs), was conducted over a 2-month period. Determinations included buffer uptake, mass and molecular weight loss and rhBMP-2 release from the unitary devices. CMC devices imbibed approximately 16 times their weight of buffer, while with MC, equilibrium uptake was approximately 6 times the dry weight of the devices. Overall mass loss percentages were approximately 55 and 35%, respectively, for CMC and MC devices. rhBMP-2 release from the devices was essentially a triphasic process: an initial phase during which "free" protein (rhBMP-2 present on the surface and within the pores of the PLGA BEPs) was released, a lag period during which no release was discerned, and then release of "bound" rhBMP-2 (protein adsorbed to the BEPs). The release of bound protein correlated with the mass loss of the polymer which began after 3 weeks. Release from the unitary devices was lower than that from the BEPs alone, due to a retardation effect of the gelled CMC/MC polymers. In rabbits in which full-thickness cranial bone defects were created, the implants were well tolerated and induced significant new bone growth during an 8-week evaluation period. The CMC devices appear to have induced bone earlier (at 2 weeks), but this did not affect eventual 8-week results. CMC devices without rhBMP-2 appeared to provide some bone conduction, in contrast to the blank MC devices.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9552343     DOI: 10.3109/10837459609029891

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  5 in total

1.  Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix.

Authors:  B H Woo; B F Fink; R Page; J A Schrier; Y W Jo; G Jiang; M DeLuca; H C Vasconez; P P DeLuca
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

2.  Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model.

Authors:  Zarana S Patel; Simon Young; Yasuhiko Tabata; John A Jansen; Mark E K Wong; Antonios G Mikos
Journal:  Bone       Date:  2008-07-14       Impact factor: 4.398

3.  Effect of a freeze-dried CMC/PLGA microsphere matrix of rhBMP-2 on bone healing.

Authors:  J A Schrier; B F Fink; J B Rodgers; H C Vasconez; P P DeLuca
Journal:  AAPS PharmSciTech       Date:  2001-10-07       Impact factor: 3.246

4.  Porous bone morphogenetic protein-2 microspheres: polymer binding and in vitro release.

Authors:  J A Schrier; P P DeLuca
Journal:  AAPS PharmSciTech       Date:  2001-10-07       Impact factor: 3.246

5.  COMP-angiopoietin1 potentiates the effects of bone morphogenic protein-2 on ischemic necrosis of the femoral head in rats.

Authors:  Lu Zhou; Sun Jung Yoon; Kyu Yun Jang; Young Jae Moon; Sajeev Wagle; Kwang Bok Lee; Byung-Hyun Park; Jung Ryul Kim
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.